RIGL | tickerfilter.com

Fundamental analysis

39%

Profitability 43%

Dept financing 25%

Liquidity 75%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1.95%

1 Month

-7.70%

3 Months

4.02%

6 Months

44.80%

1 Year

1,396.99%

2 Year

1,136.65%

Key data

Stock price

$19.91

P/E Ratio

16.95

DAY RANGE

$19.71 - $20.56

EPS

$0.79

52 WEEK RANGE

$0.79 - $29.82

52 WEEK CHANGE

$1,363.97

MARKET CAP

296.285 M

YIELD

N/A

SHARES OUTSTANDING

17.595 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

3.54

PUBLIC FLOAT

AVERAGE 10 VOLUME

$280,540

AVERAGE 30 VOLUME

$221,588

Company detail

CEO: Raul R. Rodriguez
Region: US
Website: rigel.com
Employees: 160
IPO year: 2000

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Rigel Pharmaceuticals, Inc. discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the. treatment of warm autoimmune hemolytic anemia.

RIGL - RIGEL PHARMACEUTICALS INC